Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-11-19

Clinical Trial Update: Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating BRL29060A (paroxetine hydrochloride hydrate) for PTSD was terminated with results posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BRL29060A (paroxetine hydrochloride hydrate)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Post-Traumatic Stress Disorder, Stress Disorders, Post-Traumatic | Phase 2 | Status: TERMINATED | Results posted: 2009-11-19